Strengthening disease outbreak response in the Pacific
When women thrive in science, we all benefit
Championing midwifery education across the Pacific
5 years after COVID began, outstanding fines mean marginalised Australians are still paying the highest price
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
Agency in young people’s unsafe abortion trajectories in Papua New Guinea.
Why the Delay? A Quality Improvement Initiative for Delayed Cord Clamping in Pr...
Unpacking diverse pathways to adolescent pregnancy in Cambodia: Qualitative rese...
Synthesising enablers and barriers to hepatocellular carcinoma surveillance-A sy...
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Appeals
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing biologic and small molecule therapeutics that have potential application in women's health, infectious disease & immunological conditions.
Find us at BIO 2024 this June.
In collaboration with Monash Institute of Pharmaceutical Sciences (MIPS), we are developing next-gen...
A small molecule therapeutic to potentially combat a variety of conditions affecting women’s sexual ...
A potentially broad spectrum Fc-fusion protein to treat SARS-CoV-2, comprising ACE2 (SARS-CoV-2 rece...
